A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the effect of LCQ when added to metformin.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Metformin; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• HbA1c from 7.0-10.0%, Stable Metformin dose

Exclusion Criteria:

• CHF Class III-IV, Liver disease

Other protocol-defined inclusion/exclusion criteria may apply